Top

Published in:

01-01-2020 | Hepatocellular Carcinoma | Abdominal Radiology

Characterization of liver nodules in patients with chronic liver disease by MRI: performance of the Liver Imaging Reporting and Data System (LI-RADS v.2018) scale and its comparison with the Likert scale

Authors: Andrea Esposito, Valentina Buscarino, Dario Raciti, Elena Casiraghi, Matteo Manini, Pietro Biondetti, Laura Forzenigo

Published in: La radiologia medica | Issue 1/2020

Abstract

Objectives

To evaluate the performance of the LI-RADS v.2018 scale by comparing it with the Likert scale, in the characterization of liver lesions.

Methods

A total of 39 patients with chronic liver disease underwent MR examination for characterization of 44 liver lesions. Images were independently analyzed by two radiologists using the LI-RADS scale and by another two radiologists using the Likert scale. The reference standard used was either histopathological evaluation or a 4-year MRI follow-up. Receiver operating characteristic analysis was performed.

Results

The LI-RADS scale obtained an accuracy of 80%, a sensitivity of 72%, a specificity of 93%, a positive predictive value (PPV) of 93% and a negative predictive value (NPV) of 70%, while the Likert scale achieved an accuracy of 79%, a sensitivity of 73%, a specificity of 87%, a PPV of 89% and a NPV of 70%. The area under the curve (AUC) was 85% for the LI-RADS scale and 83% for the Likert scale. The inter-observer agreement was strong (k = 0.89) between the LI-RADS evaluators and moderate (k = 0.69) between the Likert evaluators.

Conclusions

There was no statistically significant difference between the performances of the two scales; nevertheless, we suggest that the LI-RADS scale be used, as it appeared more objective and consistent.

Sersté T, Barrau V, Ozenne V et al (2012) Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology 55(3):800–806. https://doi.org/10.1002/hep.24746 CrossRefPubMed

Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA (2014) Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 109(4):542–553. https://doi.org/10.1038/ajg.2014.11 CrossRefPubMedPubMedCentral

Törner A, Stokkeland K, Svensson Å et al (2017) The underreporting of hepatocellular carcinoma to the Cancer Register and a log-linear model to estimate a more correct incidence. Hepatology 65(3):885–892. https://doi.org/10.1002/hep.28775 CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 CrossRef

Ringehan M, McKeating JA, Protzer U (2017) Viral hepatitis and liver cancer. Philos Trans R Soc B 372(1732):20160274. https://doi.org/10.1098/rstb.2016.0274 CrossRef

Mittal S, El-Serag HB (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 47(Suppl):S2–S6. https://doi.org/10.1097/mcg.0b013e3182872f29 CrossRefPubMedPubMedCentral

Jha RC, Mitchell DG, Weinreb JC et al (2014) LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas. AJR Am J Roentgenol 203(1):48–69. https://doi.org/10.2214/ajr.13.12169 CrossRef

Kim SY, An J, Lim YS et al (2017) MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol 3(4):456–463. https://doi.org/10.1001/jamaoncol.2016.3147 CrossRefPubMedPubMedCentral

Rosiak G, Podgorska J, Rosiak E, Cieszanowski A (2018) Comparison of LI-RADS vol 2017 and ESGAR guidelines imaging criteria in HCC diagnosis using MRI with hepatobiliary contrast agents. Biomed Res Int. https://doi.org/10.1155/2018/7465126 CrossRefPubMedPubMedCentral

10.

Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS (2005) Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 11(3):281–289. https://doi.org/10.1002/lt.20357 CrossRefPubMed

11.

Lima PH, Fan B, Bérubé J et al (2019) Cost-utility analysis of imaging for surveillance and diagnosis of hepatocellular carcinoma. AJR Am J Roentgenol 17:1–9. https://doi.org/10.2214/ajr.18.20341 CrossRef

12.

Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26(4):921–931. https://doi.org/10.1007/s00330-015-3900-3 CrossRefPubMed

13.

Cruite I, Tang A, Sirlin CB (2013) Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol 201(1):41–55. https://doi.org/10.2214/ajr.13.10570 CrossRefPubMed

14.

Santillan CS, Tang A, Cruite I, Shah A, Sirlin CB (2014) Understanding LI-RADS. A primer for practical use. Magn Reson Imaging Clin N Am 22(3):337–352. https://doi.org/10.1016/j.mric.2014.04.007 CrossRefPubMed

15.

Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsaves KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB (2018) Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830. https://doi.org/10.1148/radiol.2018181494 CrossRefPubMedPubMedCentral

16.

Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, Kono Y, Santillan C (2018) LI-RADS^® ancillary features on CT and MRI. Abdom Radiol 43(1):82–100. https://doi.org/10.1007/s00261-017-1220-6 CrossRef

17.

Likert R (1932) A technique for the measurement of attitudes. Arch Psychol 22(140):1–55

18.

Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L (2006) Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176(6 pt 1):2432–2437CrossRef

19.

Mitchell DG, Bruix J, Sherman M, Sirlin CB (2015) LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology 61(3):1056–1065. https://doi.org/10.1002/hep.27304 CrossRefPubMed

20.

Sofue K, Burke LMB, Nilmini V et al (2017) Liver imaging reporting and data system category 4 observations in MRI: risk factors predicting upgrade to category 5. J Magn Reson Imaging 46(3):783–792. https://doi.org/10.1002/jmri.25627 CrossRefPubMed

21.

Forner A, Vilana R, Ayuso C et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1):97–104. Erratum in: Hepatology 47(2):769. https://doi.org/10.1002/hep.21966 CrossRef

22.

Kojiro M, Roskams T (2005) Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 25(2):133–142. https://doi.org/10.1055/s-2005-871193 CrossRefPubMed

23.

Fraum TJ, Tsai R, Rohe E et al (2018) Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the Liver Imaging Reporting and Data System version 2014. Radiology 286(1):158–172. https://doi.org/10.1148/radiol.2017170114 CrossRefPubMed

24.

Zhang YD, Zhu FP, Xu X, Wang Q, Wu CJ, Liu XS, Shi HB (2016) Classifying CT/MR findings in patients with suspicion of hepatocellular carcinoma: comparison of liver imaging reporting and data system and criteria-free Likert scale reporting models. J Magn Reson Imaging 43(2):373–383. https://doi.org/10.1002/jmri.24987 CrossRefPubMed

25.

Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, Kim YH, Han JK, Choi BI (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 275(1):97–109. https://doi.org/10.1148/radiol.14140690 CrossRefPubMed

26.

Ren AH, Zhao PF, Yang DW, Du JB, Wang ZC, Yang ZH (2019) Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging. https://doi.org/10.1002/jmri.26640 CrossRefPubMed

27.

Choi SH, Byun JH, Kim SY et al (2016) Liver Imaging Reporting and Data System v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Invest Radiol 51(8):483–490. https://doi.org/10.1097/rli.0000000000000258 CrossRefPubMed

28.

Cha DI, Jang KM, Kim SH et al (2017) Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging. Eur Radiol 27(10):4394–4405. https://doi.org/10.1007/s00330-017-4804-1 CrossRefPubMed

29.

Joo I, Lee JM, Lee DH et al (2017) Liver Imaging Reporting and Data System v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: comparison with multiphasic multidetector computed tomography. J Magn Reson Imaging 45(3):731–740. https://doi.org/10.1002/jmri.25406 CrossRefPubMed

30.

Barth BK, Donati OF, Fischer MA et al (2016) Reliability, validity, and reader acceptance of LI-RADS-an in-depth analysis. Acad Radiol 23(9):1145–1153. https://doi.org/10.1016/j.acra.2016.03.014 CrossRefPubMed

31.

Petruzzi N, Mitchell D, Guglielmo F et al (2013) Hepatocellular carcinoma likelihood on MRI exams: evaluation of a standardized categorization system. Acad Radiol 20(6):694–698. https://doi.org/10.1016/j.acra.2013.01.016 CrossRefPubMed

32.

Davenport MS, Khalatbari S, Liu PS, Maturen KE, Kaza RK, Wasnik AP, Al-Hawary MM, Glazer DI, Stein EB, Patel J, Somashekar DK, Viglianti BL, Hussain HK (2014) Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology 272(1):132–142. https://doi.org/10.1148/radiol.14131963 CrossRefPubMedPubMedCentral

33.

Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, Han JK, Choi BI (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 45(2):96–103. https://doi.org/10.1097/rli.0b013e3181c5faf7 CrossRefPubMed

Title: Characterization of liver nodules in patients with chronic liver disease by MRI: performance of the Liver Imaging Reporting and Data System (LI-RADS v.2018) scale and its comparison with the Likert scale
Authors: Andrea Esposito
Valentina Buscarino
Dario Raciti
Elena Casiraghi
Matteo Manini
Pietro Biondetti
Laura Forzenigo
Publication date: 01-01-2020
Publisher: Springer Milan
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: La radiologia medica / Issue 1/2020
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-019-01092-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Characterization of liver nodules in patients with chronic liver disease by MRI: performance of the Liver Imaging Reporting and Data System (LI-RADS v.2018) scale and its comparison with the Likert scale

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study

Efficacy of ADAPT with large-bore reperfusion catheter in anterior circulation acute ischemic stroke: a multicentric Italian experience

Ultrasound and interstitial lung disease: use and limitations

Computed tomography-guided microcoil placement for localizing small pulmonary nodules before uniportal video-assisted thoracoscopic resection

Clinical features of pulmonary cryptococcosis in thin-section CT in immunocompetent and non-AIDS immunocompromised patients

CT imaging markers to improve radiation toxicity prediction in prostate cancer radiotherapy by stacking regression algorithm